Keryx Licenses Japanese Rights For Zerenex To Japan Tobacco In $100 Million Deal
This article was originally published in PharmAsia News
Executive Summary
Keryx Biopharmaceuticals got a major boost Sept. 26 in its effort to bring the Phase II hyperphosphatemia candidate Zerenex to the worldwide market by signing a licensing agreement potentially worth up to $100 million with Japan Tobacco and its subsidiary, Torii Pharmaceutical